International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.
暂无分享,去创建一个
Ivan Martin | John Barrett | Donald G Phinney | Francesco Dazzi | Peiman Hematti | Sowmya Viswanathan | Daniel J Weiss | Massimo Dominici | Jacques Galipeau | Adrian P Gee | Luc Sensebe | I. Martin | S. Viswanathan | L. Ortiz | M. Krampera | D. Stroncek | J. Galipeau | M. Mendicino | M. Dominici | W. Fibbe | Yufang Shi | A. Gee | F. Dazzi | L. Sensébé | J. Barrett | P. Hematti | D. Phinney | R. Deans | K. Leblanc | D. Weiss | Mauro Krampera | Yufang Shi | Robert J Deans | Joost DeBruijn | Willem E Fibbe | Jeffery M Gimble | Mickey B C Koh | Katarina LeBlanc | Ian K McNiece | Michael Mendicino | Steve Oh | Luis Ortiz | Valerie Planat | David F Stroncek | M. Koh | I. Mcniece | V. Planat | J. Gimble | Steve Oh | Joost DeBruijn
[1] F. Lin,et al. Mesenchymal stem cells are injured by complement after their contact with serum. , 2012, Blood.
[2] K. Keyvanfar,et al. Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency. , 2015, Cytotherapy.
[3] D. Prockop,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.
[4] N. Rouas-Freiss,et al. Concise review: Combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy , 2013, Stem cells.
[5] Wei Cao,et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications , 2014, Nature Immunology.
[6] D. Eberli,et al. Bone marrow-derived mesenchymal stromal cells improve vascular regeneration and reduce leukocyte-endothelium activation in critical ischemic murine skin in a dose-dependent manner. , 2014, Cytotherapy.
[7] M. Tremblay,et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. , 2008, Blood.
[8] L. Gaboury,et al. Adoptive transfer of mesenchymal stromal cells accelerates intestinal epithelium recovery of irradiated mice in an interleukin-6-dependent manner. , 2012, Cytotherapy.
[9] R. Romieu-Mourez,et al. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing , 2011, Cytotherapy.
[10] Arnold I Caplan,et al. Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models , 2012, Nature Neuroscience.
[11] L. Dürselen,et al. TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. , 2014, The Journal of investigative dermatology.
[12] J. Galipeau,et al. IDO-Independent Suppression of T Cell Effector Function by IFN-γ–Licensed Human Mesenchymal Stromal Cells , 2014, The Journal of Immunology.
[13] Akira Ohshima,et al. Human mesenchymal stem cells as a stable source of VEGF‐producing cells , 2008, Journal of tissue engineering and regenerative medicine.
[14] Y. Wang,et al. Functional RIG-I-like receptors control the survival of mesenchymal stem cells , 2013, Cell Death and Disease.
[15] M. Casey,et al. Keratinocyte growth factor expression in the mesenchymal cells of human amnion. , 1997, The Journal of clinical endocrinology and metabolism.
[16] C. Shao,et al. Inflammatory Cytokine-Induced Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 in Mesenchymal Stem Cells Are Critical for Immunosuppression , 2010, The Journal of Immunology.
[17] P. McCarthy,et al. Monocyte Chemotactic Protein‐3 Is a Myocardial Mesenchymal Stem Cell Homing Factor , 2007, Stem cells.
[18] J. Lévesque,et al. Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. , 2008, Stem cells and development.
[19] M. Bernard,et al. Inhibition of human mesenchymal stem cell-derived adipogenesis by the environmental contaminant benzo(a)pyrene. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.
[20] Robert Deans. Towards the creation of a standard MSC line as a calibration tool. , 2015, Cytotherapy.
[21] S. Chouaib,et al. TLR Ligands Stimulation Protects MSC from NK Killing , 2014, Stem cells.
[22] R. Handgretinger,et al. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. , 2010, Blood.
[23] T. Yamashita,et al. The role of CCL5 in the ability of adipose tissue-derived mesenchymal stem cells to support repair of ischemic regions. , 2014, Stem cells and development.
[24] M. Endres,et al. Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2 , 2007, Journal of cellular biochemistry.
[25] Shuo Huang,et al. Low Intensity Pulsed Ultrasound Enhanced Mesenchymal Stem Cell Recruitment through Stromal Derived Factor-1 Signaling in Fracture Healing , 2014, PloS one.
[26] Yuanlin Liu,et al. CCR7 Guides Migration of Mesenchymal Stem Cell to Secondary Lymphoid Organs: A Novel Approach to Separate GvHD from GvL Effect , 2014, Stem cells.
[27] L. Catrysse,et al. A20 in inflammation and autoimmunity. , 2014, Trends in immunology.
[28] Xia Xu,et al. IFN-γ-Secreting-Mesenchymal Stem Cells Exert an Antitumor Effect In Vivo via the TRAIL Pathway , 2014, Journal of immunology research.
[29] Glyn Stacey,et al. Soliciting Strategies for Developing Cell-Based Reference Materials to Advance Mesenchymal Stromal Cell Research and Clinical Translation , 2014 .
[30] K. Tarte,et al. Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. , 2013, Cytotherapy.
[31] B. Brew,et al. Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. , 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[32] Joelle Dulong,et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. , 2013, Stem cells and development.
[33] Armand Keating,et al. Mesenchymal stromal cells , 2006, Stem Cell Biology and Regenerative Medicine.
[34] L. Isola,et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[35] Philippe M. Campeau,et al. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. , 2009, Blood.
[36] Jacques Galipeau,et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[37] Yu-hua Chen,et al. The Involvement of CXCL11 in Bone Marrow-Derived Mesenchymal Stem Cell Migration Through Human Brain Microvascular Endothelial Cells , 2014, Neurochemical Research.
[38] Ilona Reischl,et al. Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use. , 2015, Regenerative medicine.
[39] R. Romieu-Mourez,et al. Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype1 , 2009, The Journal of Immunology.
[40] M. Krampera,et al. Mesenchymal stromal cell ‘licensing’: a multistep process , 2011, Leukemia.
[41] R. Puri,et al. MSC-based product characterization for clinical trials: an FDA perspective. , 2014, Cell stem cell.
[42] G. Rainger,et al. Mesenchymal Stem Cells Exhibit Firm Adhesion, Crawling, Spreading and Transmigration across Aortic Endothelial Cells: Effects of Chemokines and Shear , 2011, PloS one.
[43] G. Gibson,et al. Mesenchymal Stromal Cells Derived From Crohn's Patients Deploy Indoleamine 2,3-dioxygenase-mediated Immune Suppression, Independent of Autophagy. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[44] P. Neth,et al. Scientific category: Stem cells in hematology MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines , 2006 .
[45] E. Colletti,et al. Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage , 2012, PloS one.
[46] S. Smirnov,et al. Down-Regulation of MHC II in Mesenchymal Stem Cells at High IFN-γ Can Be Partly Explained by Cytoplasmic Retention of CIITA1 , 2008, The Journal of Immunology.
[47] Darwin J. Prockop,et al. Short-Term Exposure of Multipotent Stromal Cells to Low Oxygen Increases Their Expression of CX3CR1 and CXCR4 and Their Engraftment In Vivo , 2007, PloS one.
[48] Jacques Galipeau,et al. The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. , 2015, Cytotherapy.
[49] L. Ortiz,et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury , 2007, Proceedings of the National Academy of Sciences.
[50] K. Tsoyi,et al. Mesenchymal Stromal Cells Improve Survival During Sepsis in the Absence of Heme Oxygenase‐1: The Importance of Neutrophils , 2013, Stem cells.
[51] S. Zahler,et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling , 2012, Proceedings of the National Academy of Sciences.
[52] C. Meijer,et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? , 2002, Blood.
[53] Rochelle Cutrone,et al. Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. , 2012, Cytotherapy.
[54] E. Joe,et al. Immune following suppression mesenchymal stem cell transplantation in the ischemic brain is mediated by TGF-β , 2013, Neurobiology of Disease.
[55] M. Pittenger,et al. MSCs: science and trials , 2013, Nature Medicine.